CJC-1295 without DAC + Ipamorelin
The community's most carefully planned GH pair
Experimental material. Read before using anything from here.
Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.
Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.
Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.
Summary
The most widespread GH combination in the research community. CJC-1295 mimics the body's GHRH signal, telling the pituitary to produce GH. Ipamorelin acts through another door, the ghrelin pathway. Because they use different receptors, the combined effect on the GH pulse is greater than either alone.
Quick reference
- Reconstitution
- Vial of 20 mg blend + 3.0 mL of bacteriostatic water → 6.67 mg/mL in total (3.33 mg/mL of each).
- Schedule
- The most common is 1×/day SC, on an empty stomach, before bed.
- Measure
- On a U-100, 6 units = 0.06 mL = 200 mcg of each peptide, in a 20 mg blend in 3.0 mL.
- Status
- Not approved. Each compound has its own human data; the combined blend has no published RCT.
Titration plan (1×/day)
| Week | Dose (each peptide) | Insulin units | Volume |
|---|---|---|---|
| Weeks 1-2 | 100 mcg | 3 units | 0.03 mL |
| Weeks 3-4 | 150 mcg | 4.5 units | 0.045 mL |
| Weeks 5-8 | 200 mcg | 6 units | 0.06 mL |
| Weeks 9-12 | 200-300 mcg | 6-9 units | 0.06-0.09 mL |
Separate-Vial Reconstitution
| Vial | BAC water added | Concentration | 200 mcg dose |
|---|---|---|---|
| CJC-1295 10 mg | 3.0 mL | 3.33 mg/mL | 6 units (0.06 mL) |
| Ipamorelin 10 mg | 3.0 mL | 3.33 mg/mL | 6 units (0.06 mL) |
Cycle Guidelines
| Approach | On Cycle | Off period | Notes |
|---|---|---|---|
| Standard | 8–12 weeks | 4 weeks | Most common research-planning structure. |
| Extended | 16 weeks | 8 weeks | Used for longer-arc plans; off-period helps reset receptor sensitivity. |
| Short test | 4-6 weeks | 4 weeks | Used for short tolerability windows or budget-limited plans. |
Reconstitution by Format
| BAC water added | Total concentration | Per peptide | Common 200 mcg dose |
|---|---|---|---|
| 2.0 mL | 10.0 mg/mL total (5.0 mg/mL each) | 5.0 mg/mL | 4 units (0.04 mL) |
| 2.5 mL | 8.0 mg/mL total (4.0 mg/mL each) | 4.0 mg/mL | 5 units (0.05 mL) |
| 3.0 mL | 6.67 mg/mL total (3.33 mg/mL each) | 3.33 mg/mL | 6 units (0.06 mL) |
CJC-1295 + Ipamorelin Timeline & What to Monitor
| Window | What is commonly reported | What is being measured |
|---|---|---|
| Weeks 1-2 | Improved sleep depth, more vivid dreams, mild water retention. | Subjective sleep, recovery. |
| Weeks 3-4 | Better recovery from training, reduced soreness. | Subjective recovery, training tolerance. |
| Weeks 5-8 | Body composition shifts begin (lean mass, fat distribution). | Body weight, waist circumference, optional DEXA. |
| Weeks 8–12 | Plateauing of subjective effects; receptor sensitivity discussion begins. | IGF-1, glucose, joint symptoms. |
| Post-cycle (4 weeks) | Subjective effects taper as GH/IGF-1 axis returns toward baseline. | Repeat IGF-1 to confirm return to baseline. |
CJC-1295 + Ipamorelin vs Sermorelin, MK-677, and GHRP-2
| Comparison | vs CJC-1295 + Ipamorelin |
|---|---|
| Sermorelin (alone or with Ipamorelin) | Sermorelin is the original GHRH analog (FDA-approved 1997 for pediatric GH deficiency, withdrawn 2008). Stronger human evidence base, but very short half-life (10-12 minutes) and lower bioavailability. Pairs with Ipamorelin similarly. Researchers often choose Sermorelin when published evidence depth matters more than convenience. |
| Tesamorelin + Ipamorelin blend | The Tesamorelin + Ipamorelin blend swaps CJC-1295 for tesamorelin, an FDA-approved GHRH analog in HIV-associated lipodystrophy. It uses different vial ratios and dose math, so it should be planned from its own protocol rather than treated as a CJC-1295 substitute. |
| CJC-1295 with DAC alone | The 5.8–8.1 day half-life of DAC allows weekly dosing and is more convenient, but produces sustained GHRH stimulation instead of pulses. It pairs poorly with ipamorelin's pulsatile mechanism. It is better suited to standalone weekly plans. |
| MK-677 (Ibutamoren) | Oral ghrelin mimetic. No injections, but produces continuous GH elevation similar to CJC-1295 DAC, with greater appetite increase and possible insulin sensitivity issues over months. CJC-1295 + Ipamorelin offers more precise timing control. |
| GHRP-2 + GHRH analog | GHRP-2 is more potent than ipamorelin at raw GH stimulation. In exchange, it raises cortisol, prolactin and appetite (food intake rose ~36% in one study). Anyone who wants minimal impact on cortisol and prolactin picks ipamorelin. |
Storage and handling
The rules below apply to practically every lyophilized peptide in this reference. Where a compound has its own requirement, it appears in the table in the previous section.
- Lyophilized powder, sealed: refrigerator, between 2 and 8 °C, protected from light. Many tolerate room temperature for short transport periods, but that is tolerance, not a recommendation.
- After reconstitution: always refrigerated, between 2 and 8 °C. The stability window drops to days or a few weeks, depending on the compound.
- Never freeze after reconstituting. The freeze–thaw cycle degrades the peptide.
- Do not shake. Swirl the vial slowly. Shaking breaks the peptide chain.
- Bacteriostatic water down the wall of the vial, in a slow stream, not squirted directly onto the powder.
- Cloudy solution, with particles or a color change: discard. There is no recovery.
Lab tests and monitoring
This list is the one that appears recurrently in the source, with small variations by compound. It serves as a starting point for a conversation with a professional — not as a substitute for that conversation.
- Before starting: complete blood count, comprehensive metabolic panel, lipid panel, fasting glucose and HbA1c, TSH and free T4, blood pressure and resting heart rate.
- Depending on the compound: IGF-1 (GH axis), lipase and amylase (VIP and the incretin agonists), serum copper and ceruloplasmin (GHK-Cu and blends containing it), CRP.
- Reassessment: most protocols review between week 4 and week 8, and then every 8–12 weeks.
- Do not wait for the routine lab test in the face of abdominal pain, visual changes, a change in a mole, shortness of breath, asymmetric swelling or any new and persistent symptom. That is a reason to seek care, not a spreadsheet item.
Evidence limits
Data source: peptidedosingprotocols.com, accessed on September 3, 2026. Translation and organization in Portuguese are original work. No primary source (PubMed, trial registry, package insert) was checked in building this page — the check was against the secondary source, and that alone.